Skip to main content

Search

Reset all filters
653 Result(s)
Sort by

Respiratory

Respiratory

Human Pharma Clinical Pipeline Respiratory therapeutic area
Submit Your Opportunity

Submit Your Opportunity

Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
Our goal of transforming the treatment of neuroendocrine carcinomas

Our goal of transforming the treatment of neuroendocrine carcinomas

Our progress in developing a potential DLL3 targeted immunotherapy for neuroendocrine carcinomas (NECs), including small cell lung cancer (SCLC), large cell NEC of the lung (LCNEC-L) and extrapulmonary NEC (epNEC).
“Rare diseases are quite common”

“Rare diseases are quite common”

Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
Emmanuelle leads a team of scientists

Emmanuelle leads a team of scientists

Want to work for a company that allows you to grow your career? Emmanuelle talks about her job journey at Boehringer Ingelheim.
"To join Boehringer Ingelheim was the best ever decision"

"To join Boehringer Ingelheim was the best ever decision"

Pharmacologist Michael Mark worked for us for 34 years. He played a key role in the research and development of several medications. Watch our video and discover our job opportunities.
Fight against COVID-19 pandemic

Fight against COVID-19 pandemic

Press release on Boehringer Ingelheim's half-year figures 2020. Business development from January to June 2020.
Candice is moving to Germany

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.
Solidarity with Ukraine

Solidarity with Ukraine

Our company condemns the military aggression against Ukraine and is committed to helping those in need in the longer term with monetary and in kind donations